DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVoxâ„¢ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects… Continue reading DelNova: Addressing complications from Botox (217)